Pulmonary fellow Ellen Suder (MED26,26) working in the high containment lab, BSL-4, at BUs National Emerging Infectious Diseases Laboratories (NEIDL). Photo by Cydney Scott
School of MedicineBUs longest running federally funded training program began in 1975
When the School of Medicine training program called Biology of the Lung: A Multidisciplinary Program began, on July 1, 1975, Gerald Ford was president, all four Beatles were alive, and gas cost about 50 cents a gallon.
I was in elementary school when this started, so I wasnt spending a lot of time thinking about lung biology or pulmonary disease or anything else, Joseph Mizgerd, now program coprincipal investigator, says with a smile.
The National Institutes of Health (NIH) has funded Biology of the Lung from the beginning and has just renewed it for five more years, taking it through years 46 to 50 of training predoctoral and postdoctoral scientists, both PhDs and MDs, in lung biology and pulmonary disease. The $4.1 million renewal will fund stipends and other expenses for a dozen trainees a year until 2026.
While Biology of the Lung appears to be the longest running grant-funded training program at the University, the scientists who run it would much rather talk about the innovative idea at its core.
There are certain well-worn, traditional paths in training a doctor or a researcher, and this program is not one of those. Its very different, says Darrell Kotton, who joined Mizgerd as a coprincipal investigator on the grant this summer.
Mizgerd, the Jerome S. Brody, MD, Professor of Pulmonary Medicine, is a MED professor of medicine, microbiology, and biochemistry and BU Pulmonary Center director. Kotton, the David C. Seldin Professor of Medicine, is a MED professor of medicine and pathology and founding director of the Center for Regenerative Medicine (CReM).
But zoom in: Kotton is an MD. Mizgerd is an ScD. Their partnership mirrors what the program is about.
The well-worn paths are: if you decide to become a doctor, you go through medical residency and a fellowship and get a job as a clinician, Kotton says. If you decide to be a researcher, you get a PhD in grad school and go through a postdoc and get a job in a company or a university as a researcher. This program is neither of those. Its the synergy of the two, the interface of the two.
Clinical and research trainees are thrown together in the same laboratories and seminar rooms, start talking, and ultimately train each other. Each is also assigned a faculty mentor. The result is greater than the sum of its parts.
The PhD scientists learn about the clinical questions that are most vexing for physicians, what sorts of clinical materials might be available to help empower their biological research, and how scientific discoveries can powerfully impact the prevention, diagnosis, or cure of pulmonary diseases.
You have these unique researchers that get an impressive breadth of understanding of what are the clinical issues that a patient suffers from and what is the true biology thats going on in the lung when things go wrong in patients, and come up with some really interesting ideas in the lab about how to make them go right, Kotton says.
On the other side, Mizgerd says, by working with the basic scientists, the MDs learn the application of scientific rigor and how best to ask research questions like: What genes do when they get turned on or off in the lungs, and how that affects pulmonary diseases, such as which immune cells get summoned in response to infections or allergens or pollutants, why some lung cells get too twitchy in asthma, or which cells are responsible for the stiffening of fibrotic lungs.
I was 100 percent a clinician at the time I arrived on campus in 1998, says Kotton, who graduated from this same program he now coleads more than two decades later. They gave me a lab opportunity that unexpectedly attracted me to basic science research. I changed my career as a result of this program, to a physician/scientist track, and so it has really affected my life and experience in delivering care and research to the community.
Of course pulmonary specialists have been much in demandand in the newssince COVID-19 arrived on the scene, but the two PIs say that the SARS-CoV-2 virus wasnt really a factor in the grants renewal. There was already a tremendous need for more lung disease researchers, a high priority for the NIH.
Many prominent pulmonary scientists at BU and elsewhere first passed through the Biology of the Lung program as trainees.
The training grant had a huge impact on my career trajectory, says Avrum Spira (ENG02), BUs Alexander Graham Bell Professor in Health Care Entrepreneurship, a MED professor of medicine, pathology, and bioinformatics, and the global head of the Lung Cancer Initiative at Johnson & Johnson. It allowed me to go back to school and get training in the emerging field of bioinformatics, which in turn catalyzed the launch of my career as a physician-scientist in the field of computational genomics.
Others include Sharon Rounds, a Brown Medical School professor of medicine and of pathology and laboratory medicine and a past president of the American Thoracic Society; Rebecca Kusko (MED15,15), Immuneering Corporation vice president, business development and corporate affairs; and Alicia Wooten (MED19), a Gallaudet University assistant professor of science, technology, accessibility, mathematics, and public health biology.
When I came out of residency, I already knew I was looking for a research-oriented fellowship, but I wanted one that would give me excellent clinical training too, says Burton Dickey, Clifton Howe Distinguished Professor of Pulmonary Medicine and for 20 years the chief of pulmonary medicine at the University of Texas MD Anderson Cancer Center in Houston, who was a trainee in the program in the 1980s before briefly joining BUs faculty.
I was like a kid in a candy shop, taking a course in biophysics one semester and learning the structure of lipid bilayers, and another semester taking a course on drug receptor interactions, Dickey says. There were so many outstanding basic scientists and so many opportunities to learn from them. I was so busy going from one to the next.
Some fellows have found themselves on the front lines in the pandemic.
My dissertation research actually focuses on filovirusesthats Ebola and Marburg, says Ellen Suder (MED2626), a PhD candidate in microbiology and a program trainee who has been doing a lot of COVID-related work at BUs National Emerging Infectious Diseases Laboratories (NEIDL) high-containment labs. Over the past year and a half, Ive picked up a lot of research on SARS-CoV-2. Its been a really amazing experience to be involved with all that.
The NEIDL lab where she works offered virology help to scientists around the Boston area last year as soon as the seriousness and duration of the outbreak became clear. We ended up accruing 20-plus collaborators at a bunch of labs in the Boston areaa lot of BU labs, a lot of other universities, some companies, Suder says. It was very much an all-hands-on-deck situation. I just started volunteering to take on samples that needed to be generated and things like that.
The biggest project that our lab did last year was this collaboration with Darryl Kottons lab at the CReM. We came up with all of these potential drug targets and curated a list of drugs that were either approved for something else entirely or were in clinical trials, and tested if they would be viable in preventing this infection. What we found out that was really cool was in the cell-type model we normally use they werent terribly effective at preventing infection, but in the actual stem cellderived lung cells, they worked a lot better.
Now Im really interested to see what I can do with these lung cell models, she says, studying the viruses we normally study.
Among the training programs benefits is its openness to a wide variety of research interests within the pulmonary field, says Nathan Mesfin, an MD, a MED clinical instructor, and a Pulmonary Center fellow, who was recently accepted into the School of Public Health Master of Public Health Program. He is studying how to optimize goals-of-care conversations between patients and providers, both in the ICU and outpatient settings, including end-of-life conversations.
The Biology of the Lung program has allowed him to better learn the methodology of epidemiology, take SPH courses, and build foundational knowledge in biostatistics. It leads you on the road to becoming an independent researcher, Mesfin says.
Mesfins mentor is Renda Wiener, a MED professor of medicine. Like Kotton, she was a program trainee before becoming a mentor.
For me, a lot of it is being a role model and them seeing what the job of an academic scientist looks likedoing the work, having a team of people that are pitching in to move the science forward, says Wiener, who is also associate director of the VA Boston Healthcare System Center for Healthcare Organization & Implementation Research. I really like helping people find and develop what they feel passionate about, what they want to do for the rest of their lives, and help them get there.
Being part of a half-century-old program is a very humbling experience, Mesfin says. To know that there are so many people that have gone through this process and have become very successful, like Dr. Wiener, who were sort of raised through this program. Nearly 50 years runningit is amazing.
Jerome Brody, a MED professor emeritus of medicine, founded the Biology of the Lung program with several other faculty members and was its first principal investigator. He ran the program for 25 years, passing the baton in 2001 to David Center (MED72, CAS72), Gordon and Ruth Snider Professor of Pulmonary Medicine and a MED professor of medicine and biochemistry, who ran it until 2011, when Mizgerd joined him as co-PI.
When Brody was told of the grant extension this week via Zoom, his response was, Wowthats fantastic, but hes quick to share credit with the other faculty from the 1970s and those who have come along after him. A lot of people contributed, he said. Its a good group, very smart, very dedicated, and usually right on target.
The goal was to train the PhD scientists side by side with the MD scientists, says Center, so the PhDs would learn the clinical relevance of the research with respect to human health, and the MD scientists would learn the techniques and rigors of PhD science. We still use that as the opening line of the grant, which has been pretty good to us over the years.
In the early days of the program, new tools included molecular biology. Transgenics came along later, followed by big data, RNA sequencing, and clinical outcomes analysis. The latest techniques include gene editing, stem cells, and regenerative medicine.
I imagine five years from now itll be a completely different conversation again, Kotton says, but what wont be different is the innovative nature of this cross-disciplinary training program that really breaks conventional boundaries and silos.
The whole idea here is that this is an investment in the future of science, Center says, and NIH believes that this is one of the major ways that young scientists can be trained in environments that will give them the rigor to succeed subsequently. Weve trained a lot of people whove gone on to make major contributions to our understanding of lung diseases and lung health.
Thats why they keep investing in us, he says. Were flattered, but that doesnt mean it isnt hard work.
- COVID-19: Researchers warn against overhyping early-stage therapies - Medical News Today - October 26th, 2021
- OpRegen Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D. - Yahoo Finance - October 26th, 2021
- Insights & Outcomes: Place cells, planarians, and 'prewet' proteins - Yale News - October 26th, 2021
- IMAC Holdings The Back Space Announces the Completion of Two Additional Retail Spinal Care Locations - Yahoo Finance - October 26th, 2021
- JEFFERSON PARISH PARTNERS WITH LOUISIANA DEPARTMENT OF HEALTH TO ADMINISTER FREE FLU SHOTS AND COVID-19 VACCINES ON NOVEMBER 6, 2021 - 10-25-YYYY -... - October 26th, 2021
- Male Infertility Could Be Treated With Monkey Cells; New Study Shows How These Animals Could Help Address the Condition - Science Times - October 26th, 2021
- Citius Pharmaceuticals to Host Key Opinion Leader Webcast on the Compelling Need to Salvage Central Venous Catheters in CLABSI Patients - Yahoo... - October 26th, 2021
- New findings may help widen therapeutic interventions for B-cell acute lymphoblastic leukemia - News-Medical.Net - October 25th, 2021
- Getting to Know Kate Roth at Beacon Integrative Medical Center in Rexburg - East Idaho News - October 25th, 2021
- Global Cell Therapy Market Report 2021-2028 - Growing Adoption of Regenerative Medicine & Introduction of Novel Platforms and Technologies -... - October 25th, 2021
- Vertex reports positive results for first patient in Type 1 diabetes trial - BetaBoston - October 23rd, 2021
- Morris receives grant for stem cell research - The Source - Washington University Record - October 23rd, 2021
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes - PMLiVE - October 23rd, 2021
- McLaughlin Research Institute receives $5 million gift to support neurology studies - Great Falls Tribune - October 23rd, 2021
- AML medication and treatment: What to know - Medical News Today - October 23rd, 2021
- U S Stem Cell : USRM to Focus on Animal Health and Lead Pet-Care Innovation - Marketscreener.com - October 19th, 2021
- Opinion: Why Colin Powell's death should not be framed as the death of a vaccinated person - Poynter - October 19th, 2021
- Quris combines AI with patient on a chip to speed drug development and reduce animal testing - TechCrunch - October 19th, 2021
- Dr. Helen Heslop elected to the National Academy of Medicine - Baylor College of Medicine News - October 19th, 2021
- Researchers report long-lasting effects of gene therapy in children with deadly immune disorder - News-Medical.Net - October 19th, 2021
- Coronavirus: How does misinformation spread, and how can we stop it? - The Jerusalem Post - October 17th, 2021
- Dr. Kahl on the Potential Utility of Frontline CAR T-Cell Therapy in MCL - OncLive - October 17th, 2021
- FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With Early Non-Small Cell Lung Cancer - Business Wire - October 17th, 2021
- Global Stem Cell and Primary Cell Culture Medium Market 2021 Trends and Leading Players Analysis 2027 Merck, STEMCELL Technologies, Irvinesci, Cell... - October 15th, 2021
- Dr. Erba on the Evolution of Treatment in MCL - OncLive - October 15th, 2021
- After no stem cell donors stepped up to saved her son, mom continues to help others facing the same challenge - Chicago Tribune - October 15th, 2021
- International ZIM Network: SmartMed - Regenerative Solutions for the Therapies of Tomorrow - Business Wire - October 15th, 2021
- Are 'robot massages' the future of muscle repair? - Medical News Today - October 15th, 2021
- What the FDA Panel's Moderna Booster Shot Vote Means and What's Next - NBC Chicago - October 15th, 2021
- Phase 2 Clinical Trial Data of NurOwn in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in... - October 15th, 2021
- R3 Stem Cell & Exosome Therapy: Joint & Back Pain, Avoid ... - October 13th, 2021
- Stem Cell PhD Program | Institute for Stem Cell Biology ... - October 13th, 2021
- New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease - Newswise - October 13th, 2021
- Repurposed Drug Reverses Signs of Alzheimers in Mice, Human Cells - The Scientist - October 13th, 2021
- Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development - StreetInsider.com - October 13th, 2021
- What the latest COVID research says about breakthrough cases and transmission : Shots - Health News - NPR - October 13th, 2021
- HNF collaborates with Rarebase on a Drug Discovery Platform to develop treatments for Charcot-Marie-Tooth (CMT) - PRNewswire - October 13th, 2021
- Autologous HSCT Continues to Show Sustained Benefit in MCL, But Targeted Therapies May Challenge its Role as Standard Frontline Treatment -... - October 13th, 2021
- Bartolo Coln, Winner Of The Cy Young, Wins Lawsuit In Case Of Stem Cell Treatment To Which He Was Subjected Before His Return To The Major Leagues. -... - October 11th, 2021
- The Impact Of Market Restrictions On The US Stem Cell Biomaterials Market - Med Device Online - October 11th, 2021
- Vitro Biopharma Inc. July 31st 2021; 3rd Quarter ended Financial Results of Operations and Shareholder Letter. - Yahoo Finance - October 11th, 2021
- Top US Leukemia Experts from Academia, Industry and Public Sector Coming Together at Acute Myeloid Leukemia Conference on October 22 - OncLive - October 11th, 2021
- Precision medicine data dive shows water pill may be viable to test as Alzheimer's treatment - National Institutes of Health - October 11th, 2021
- Treating Early Relapse in Follicular Lymphoma - Targeted Oncology - October 11th, 2021
- Humans and Chimpanzees Use a Part of Their DNA in Different Ways - Technology Networks - October 11th, 2021
- A stem cell treatment for MS offers some patients hope. But is it hope that will last? - WHYY - October 9th, 2021
- CAR T Offer New Treatment Option for Non-Hodgkin Lymphoma - Targeted Oncology - October 9th, 2021
- FDA Advisory Committee Recommends Maribavir to Treat Cytomegalovirus CMV Infection and Disease - Contagionlive.com - October 9th, 2021
- What surgeons are saying about regenerative medicine in 2021 - Becker's Orthopedic & Spine - October 9th, 2021
- Study illuminates how BRD4 protein directs the spatial organization of DNA within cell nucleus - News-Medical.net - October 9th, 2021
- Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple Myeloma - OncLive - October 9th, 2021
- Anti-CD47 Therapy and Other New Approaches to the Treatment of Myelodysplastic - Targeted Oncology - October 9th, 2021
- ViaCyte to Present at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa - PRNewswire - October 7th, 2021
- Seattle Stem Cell Therapy Clinic - Seattle Sports Medicine ... - October 7th, 2021
- StemExpress Partners with the Alliance for Regenerative Medicine to Provide COVID-19 Testing for the Cell and Gene Meeting on the Mesa - PRNewswire - October 7th, 2021
- New Stem Cell Approach Through Using Wavelength Laser Might have Discovered Why Humans Lose Hair - Tech Times - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - WMTV - NBC15 - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- Northwesterns SPORE has made advances in understanding the genetic basis of glioblastoma - News-Medical.Net - October 5th, 2021
- NextCure Announces New Appointments to its Board of Directors - GlobeNewswire - October 5th, 2021
- Therapy and Prevention Strategies for Myocardial Infarction | IJN - Dove Medical Press - October 3rd, 2021
- Lack of awareness about blood stem cell donation is one of the leading causes for low number of donors in In.. - ETHealthworld.com - October 3rd, 2021
- Advanced technique offers new insights about the dynamics of gliomas - News-Medical.net - October 3rd, 2021
- "Stem cell-based therapeutics poised to become mainstream option - BSA bureau - October 2nd, 2021
- The stem cell revolution isnt what you think it is - New Scientist News - October 2nd, 2021
- Stem cell agency gives out $2 million a minute - Capitol Weekly - October 2nd, 2021
- Researching the Safety and Effectiveness of Stem Cells to Treat 'Long Covid' - Entrepreneur - October 2nd, 2021
- United States Regenerative Medicine Markets to 2026: Focus on Cell Therapies, Gene Therapies, Progenitor & Stem Cell Therapies, Tissue Engineered... - October 2nd, 2021
- U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Business... - October 2nd, 2021
- Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA - Business Wire - October 2nd, 2021
- Stem Cell Umbilical Cord Blood Market in North America 2021 Sees Growth Due to Rising Spending Capacity and Suitable Payment Plans - PRNewswire - October 2nd, 2021
- BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS - BioSpace - October 2nd, 2021
- Macomics Announces New Hires that Expands its Macrophage-based Drug Discovery R&D Team - BioSpace - October 2nd, 2021
- Stanford neuroscientist's 'assembloids' pave the way for innovative brain research - Scope - October 2nd, 2021
- At the crossroads of reproductive and regenerative medicine: new opportunities for preserving and restoring fertility - ESHRE - September 25th, 2021
- Doctors Debate: Do CAR T Cells and Transplantation Both Have a Place in Aggressive B-Cell Lymphoma Treatment? - Targeted Oncology - September 25th, 2021
- Global Stem Cell Alopecia Treatment Market 2021 Development Status,Industry Insights and Forecast Research Report 2027 Stillwater Current -... - September 25th, 2021
- AML vs. ALL: Differences in symptoms, diagnosis, and survival - Medical News Today - September 25th, 2021
- New gene therapies may soon treat dozens of rare diseases - American Society for Biochemistry and Molecular Biology - September 25th, 2021
- BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program - GlobeNewswire - September 25th, 2021